Canaccord Genuity Downgrades Protalix BioTherapeutics (PLX) to Hold
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.29 +3.15%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Canaccord Genuity downgraded Protalix BioTherapeutics (NYSE: PLX) from Buy to Hold, maintains price target of $8.00.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Assicurazioni Generali SpA (G:IM) (ARZGY) to Neutral
- BWS Financial Downgrades Inter Parfums (IPAR) to Sell
- Oppenheimer Downgrades AtaiBeckley Inc (ATAI) to Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
